These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24292098)

  • 1. Time since last vaccine dose in PCR-positive and PCR-negative children with suspected pertussis to monitor pertussis vaccine effectiveness.
    Riffelmann M; Mohr J; Hellenbrand W; Wirsing von Koenig CH
    Eur J Clin Microbiol Infect Dis; 2014 May; 33(5):805-8. PubMed ID: 24292098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak.
    Witt MA; Katz PH; Witt DJ
    Clin Infect Dis; 2012 Jun; 54(12):1730-5. PubMed ID: 22423127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do we need a new vaccine to control the re-emergence of pertussis?
    Mills KH; Ross PJ; Allen AC; Wilk MM
    Trends Microbiol; 2014 Feb; 22(2):49-52. PubMed ID: 24485284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waning protection after fifth dose of acellular pertussis vaccine in children.
    Klein NP; Bartlett J; Rowhani-Rahbar A; Fireman B; Baxter R
    N Engl J Med; 2012 Sep; 367(11):1012-9. PubMed ID: 22970945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand.
    Radke S; Petousis-Harris H; Watson D; Gentles D; Turner N
    Vaccine; 2017 Jan; 35(1):177-183. PubMed ID: 27866766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
    Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
    Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of acellular pertussis vaccination during childhood (<7 years of age) for preventing pertussis in household contacts 1-9 years old in Catalonia and Navarra (Spain).
    Plans P; Toledo D; Sala MR; Camps N; Villanova M; Rodríguez R; Alvarez J; Solano R; García-Cenoz M; Barrabeig I; Godoy P; Minguell S
    Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):2059-2067. PubMed ID: 27612470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of nested Bordetella PCR in pertussis vaccine trial.
    Reizenstein E; Lindberg L; Möllby R; Hallander HO
    J Clin Microbiol; 1996 Apr; 34(4):810-5. PubMed ID: 8815088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional study of Bordetella pertussis seroprevalence and estimated duration of vaccine protection against pertussis in St. Petersburg, Russia.
    Kurova N; Timofeeva EV; Guiso N; Macina D
    Vaccine; 2018 Dec; 36(52):7936-7942. PubMed ID: 30448334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
    Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
    Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Pertussis Vaccines Protect Against Bordetella parapertussis?
    Liko J; Robison SG; Cieslak PR
    Clin Infect Dis; 2017 Jun; 64(12):1795-1797. PubMed ID: 28369240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not confounded by age or receipt of booster-doses.
    Sheridan SL; Ware RS; Grimwood K; Lambert SB
    Vaccine; 2015 Sep; 33(39):5027-30. PubMed ID: 26297874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertussis outbreak, southeastern Minnesota, 2012.
    Theofiles AG; Cunningham SA; Chia N; Jeraldo PR; Quest DJ; Mandrekar JN; Patel R
    Mayo Clin Proc; 2014 Oct; 89(10):1378-88. PubMed ID: 25282430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.
    Martin SW; Pawloski L; Williams M; Weening K; DeBolt C; Qin X; Reynolds L; Kenyon C; Giambrone G; Kudish K; Miller L; Selvage D; Lee A; Skoff TH; Kamiya H; Cassiday PK; Tondella ML; Clark TA
    Clin Infect Dis; 2015 Jan; 60(2):223-7. PubMed ID: 25301209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nested case-control study measuring pertussis vaccine effectiveness and duration of protection in Manitoba, Canada, 1992-2015: A Canadian Immunization Research Network Study.
    Wilkinson K; Righolt CH; Kwong JC; Schwartz KL; Russell ML; Crowcroft NS; Mahmud SM
    Vaccine; 2019 Nov; 37(48):7132-7137. PubMed ID: 31564453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of whole-cell versus acellular pertussis vaccine effectiveness in school clusters of pertussis, France, 2013.
    Belchior E; Guillot S; Poujol I; Thabuis A; Chouin L; Martel M; Delisle E; Six C; Guiso N; Lévy-Bruhl D
    Med Mal Infect; 2020 Oct; 50(7):617-619. PubMed ID: 32659333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time polymerase chain reaction detection of Bordetella pertussis DNA in acellular pertussis vaccines.
    Tatti KM; Slade B; Patel M; Messonnier N; Jackson T; Kirkland KB; Talbot EA; Tondella ML
    Pediatr Infect Dis J; 2008 Jan; 27(1):73-4. PubMed ID: 18162945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay.
    Fry NK; Litt DJ; Duncan J; Vaghji L; Warrener L; Samuel D; Andrews N; Harnden A; Harrison TG
    J Med Microbiol; 2013 Sep; 62(Pt 9):1281-1289. PubMed ID: 23722435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.